Molecular-Level Nanofactory NanoPharm Receives FDA Approval: Synthesizing Personalized Drugs On-Site Inside Patients' Bodies

Molecular-Level Nanofactory NanoPharm Receives FDA Approval: Synthesizing Personalized Drugs On-Site Inside Patients' Bodies

NanoPharm, an in-body drug synthesis nanosystem jointly developed by MIT's Koch Institute for Cancer Research and Roche, received FDA approval on August 24, 2030, becoming the world's first nanomedical device capable of synthesizing drugs on-site inside patients' bodies.

NanoPharm consists of injectable nanofactory capsules, each approximately 200 nanometers in diameter, containing a drug precursor storage chamber, catalytic reaction chamber, and release control module. After entering the body via intravenous injection, the system autonomously navigates to target tissue (such as tumor sites) and synthesizes the most suitable drug molecules in real time based on the local microenvironment's pH, temperature, and biomarker concentrations.

In Phase III clinical trials for advanced liver cancer, the NanoPharm group achieved a tumor shrinkage rate of 67%, compared to 23% in the traditional chemotherapy group. More importantly, the systemic side effect rate in the NanoPharm group was only one-tenth that of traditional chemotherapy, as the drugs are synthesized and released only at the tumor site.

MIT professor and NanoPharm project lead scientist Robert Langer said: "NanoPharm realizes the ultimate vision of drug development — releasing the right drug, at the right time, in the right place, at the right dose. Traditional drugs are mass-produced generic products from factories, whereas NanoPharm is personalized treatment customized on demand inside the body."

The system's core technology is the "biorthogonal catalytic reaction chamber." NanoPharm's catalytic reaction chamber uses biorthogonal chemical reactions that can convert non-toxic drug precursors into active drug molecules under physiological conditions without interfering with normal biological processes. Each nanofactory can perform up to 5 different catalytic reactions, selecting which drug to synthesize based on environmental signals.

Roche's CEO said: "NanoPharm is not just a new drug — it is an entirely new drug delivery paradigm. It transforms drugs from static molecules into dynamic responsive systems."

However, the technology also faces challenges. The long-term safety of nanofactories in the body still requires more data, and the currently approved indication is limited to advanced liver cancer. The research team plans to initiate clinical trials for breast cancer and pancreatic cancer in 2031.

NanoPharm's first treatment is priced at $180,000 per course. Roche stated it is negotiating with health insurance agencies in various countries for reimbursement inclusion.